Thiotepa 15 mg is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.
- It is for the treatment of adenocarcinoma of the breast or ovary.
- Healthcare professionals recommend this medicine for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
- Doctors use this medicine to treat superficial papillary carcinoma of the urinary bladder.
The general recommended dosage of Thiotepa in:
- Class 3 Beta-Thalassemia
- Adenocarcinoma of the Breast or Ovary
- Malignant effusions
- Superficial papillary carcinoma of the urinary bladder
Side Effects of medicine
Nausea, vomiting, abdominal pain, Fatigue, weakness, Allergic reactions, Contact dermatitis, pain at the injection site, dizziness, headache, blurred vision, Dysuria, urinary retention, chemical cystitis, or hemorrhagic cystitis, respiratory problems, etc.